Triple-Class Refractory Multiple Myeloma Associated With Poor Survival and Decline in Health-Related Quality of Life

The holistic burden of triple-class refractory multiple myeloma (TCR MM) and its associated poor prognosis is not well understood. Tang et al. used the ongoing prospective Connect® MM Registry to investigate treatment patterns and outcomes in these patients.

A total of 240 patients were identified in the Registry and retreatment was common in this cohort, although no preferred therapeutic combination was found. Overall survival for those who received <4 prior lines of therapy was 10 months, compared with 8 months for those who received >4 previous lines of therapy. A clinically meaningful decline in health-related quality of life was found in the year following index scoring across all studied assessment instruments.